390 related articles for article (PubMed ID: 14638539)
1. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
Belton OA; Duffy A; Toomey S; Fitzgerald DJ
Circulation; 2003 Dec; 108(24):3017-23. PubMed ID: 14638539
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
[TBL] [Abstract][Full Text] [Related]
3. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse.
McClelland S; Gawaz M; Kennerknecht E; Konrad CS; Sauer S; Schuerzinger K; Massberg S; Fitzgerald DJ; Belton O
Atherosclerosis; 2009 Jan; 202(1):84-91. PubMed ID: 18514659
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2.
Tanigawa T; Watanabe T; Hamaguchi M; Sasaki E; Tominaga K; Fujiwara Y; Oshitani N; Matsumoto T; Higuchi K; Arakawa T
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G148-56. PubMed ID: 12958020
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.
Burleigh ME; Babaev VR; Oates JA; Harris RC; Gautam S; Riendeau D; Marnett LJ; Morrow JD; Fazio S; Linton MF
Circulation; 2002 Apr; 105(15):1816-23. PubMed ID: 11956125
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo.
Buerkle MA; Lehrer S; Sohn HY; Conzen P; Pohl U; Krötz F
Circulation; 2004 Oct; 110(14):2053-9. PubMed ID: 15451781
[TBL] [Abstract][Full Text] [Related]
7. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice.
Burleigh ME; Babaev VR; Yancey PG; Major AS; McCaleb JL; Oates JA; Morrow JD; Fazio S; Linton MF
J Mol Cell Cardiol; 2005 Sep; 39(3):443-52. PubMed ID: 16040051
[TBL] [Abstract][Full Text] [Related]
10. COX-2 is not involved in thromboxane biosynthesis by activated human platelets.
Patrignani P; Sciulli MG; Manarini S; Santini G; Cerletti C; Evangelista V
J Physiol Pharmacol; 1999 Dec; 50(4):661-7. PubMed ID: 10639016
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice.
Burleigh ME; Babaev VR; Patel MB; Crews BC; Remmel RP; Morrow JD; Oates JA; Marnett LJ; Fazio S; Linton MF
Biochem Pharmacol; 2005 Aug; 70(3):334-42. PubMed ID: 15950196
[TBL] [Abstract][Full Text] [Related]
12. Possible role of cyclooxygenase II in the acquisition of ovarian luteal function in rodents.
Sakurai T; Tamura K; Okamoto S; Hara T; Kogo H
Biol Reprod; 2003 Sep; 69(3):835-42. PubMed ID: 12724285
[TBL] [Abstract][Full Text] [Related]
13. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
Jacob S; Laury-Kleintop L; Lanza-Jacoby S
J Surg Res; 2008 May; 146(1):135-42. PubMed ID: 17950326
[TBL] [Abstract][Full Text] [Related]
14. Constitutive expression and involvement of cyclooxygenase-2 in human megakaryocytopoiesis.
Tanaka N; Sato T; Fujita H; Morita I
Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):607-12. PubMed ID: 14726416
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis.
Zhang X; Morham SG; Langenbach R; Young DA; Xing L; Boyce BF; Puzas EJ; Rosier RN; O'Keefe RJ; Schwarz EM
J Bone Miner Res; 2001 Apr; 16(4):660-70. PubMed ID: 11315993
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice.
Babaev VR; Ding L; Reese J; Morrow JD; Breyer MD; Dey SK; Fazio S; Linton MF
Circulation; 2006 Jan; 113(1):108-17. PubMed ID: 16380543
[TBL] [Abstract][Full Text] [Related]
17. Selective cyclooxygenase-2 inhibition by nimesulide in man.
Cullen L; Kelly L; Connor SO; Fitzgerald DJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):578-82. PubMed ID: 9808683
[TBL] [Abstract][Full Text] [Related]
18. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor.
Kearney D; Byrne A; Crean P; Cox D; Fitzgerald DJ
J Am Coll Cardiol; 2004 Feb; 43(4):526-31. PubMed ID: 14975458
[TBL] [Abstract][Full Text] [Related]
19. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 and inflammation in atherosclerosis.
Linton MF; Fazio S
Curr Opin Pharmacol; 2004 Apr; 4(2):116-23. PubMed ID: 15063354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
